TXN Texas Instruments
Recovery is real and capex is fading, but at $300 the market pays for peak-cycle margins.
The story
Texas Instruments is the scale leader in analog and embedded processing. Its moat rests on a catalog of more than 80,000 parts, long industrial and auto design-in cycles, direct customer relationships and a low-cost 300mm internal fab base. The heavy 2022-2025 capex cycle is ending: capex has fallen to about 2.6B, and the cyclical recovery is under way. TTM revenue is 20.8B (+17%) and operating margin has rebuilt to 41.9% from 35.4%. It is a mature cash franchise. The open question is how much of the new capacity becomes high-margin revenue and how much becomes depreciation drag.
Two facts changed. Margins recovered faster than I expected (41.9% TTM against 35.4% last fiscal year), so I raised the target to 45%, reached in 3 years. That is still below the 51% peak because D&A from the new fabs is structurally higher. Capex has rolled off sharply while the fabs have spare capacity, so incremental sales-to-capital should run well above the depressed 0.68 trailing ratio; I raised it from 1.2 to 1.5, a 25% move. Growth, beta and horizon are unchanged; even with these changes the market still prices a stronger and longer upcycle than I do.
Value drivers
| Revenue growth (Y1) | 9.0% |
| Terminal growth | 3.5% |
| Forecast horizon | 10y |
| Target operating margin | 45.0% |
| Years to target margin | 3 |
| Sales-to-capital | 1.50 |
| Beta | 1.10 |
| Failure probability | 1.0% |
| Cost of capital (WACC) | 9.7% |
| Terminal WACC | 9.3% |
Valuation bridge
| PV of explicit FCFF | 64.30B |
| PV of terminal value | 81.46B |
| Equity value | 133.92B |
| ÷ shares → per share | $146.49 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 22.63B | 9.0% | 42.9% | 8.51B | 1.25B | 7.26B | 6.62B |
| 2 | 24.53B | 8.4% | 44.0% | 9.44B | 1.27B | 8.18B | 6.79B |
| 3 | 26.44B | 7.8% | 45.0% | 10.42B | 1.27B | 9.15B | 6.92B |
| 4 | 28.34B | 7.2% | 45.0% | 11.17B | 1.26B | 9.90B | 6.83B |
| 5 | 30.19B | 6.6% | 45.0% | 11.90B | 1.24B | 10.66B | 6.70B |
| 6 | 31.99B | 5.9% | 45.0% | 12.61B | 1.20B | 11.41B | 6.54B |
| 7 | 33.70B | 5.3% | 45.0% | 13.28B | 1.14B | 12.14B | 6.34B |
| 8 | 35.29B | 4.7% | 45.0% | 13.91B | 1.06B | 12.85B | 6.11B |
| 9 | 36.74B | 4.1% | 45.0% | 14.48B | 967.12M | 13.51B | 5.86B |
| 10 | 38.02B | 3.5% | 45.0% | 14.99B | 857.21M | 14.13B | 5.58B |
Key risks
- Industrial and auto demand stalls before the new 300mm capacity fills, leaving underabsorbed fixed costs
- Chinese analog suppliers take share and pricing in commodity parts, and tariffs complicate China sales
- The low 12.4% tax rate and CHIPS-related benefits may not last, compressing normalized earnings
Catalysts
- Free cash flow inflects as capex falls toward 10-15% of revenue, supporting dividends and buybacks
- Utilization rises at Lehi and Sherman, pushing gross margin back toward 65%+